The independent medical news service

The addition of nivolumab plus ipilimumab to first-line chemotherapy continues to be beneficial for patients with metastatic non-small-cell lung cancer with longer follow-up, show updated phase 3 trial data.

Adding nivolumab to neoadjuvant chemotherapy for resectable non-small-cell lung cancer is not associated with surgical delays or complications, show CheckMate 816 data presented at the 2021 ASCO Annual Meeting.

Five-year findings from the PACIFIC trial for patients with unresectable stage III non-small-cell lung cancer continue to show survival benefits with 1 year of durvalumab therapy versus placebo after platinum-based chemoradiotherapy.

The outcomes of treatment-naïve, advanced non-small-cell lung cancer patients with tumor PD-L1 levels of 1–49% may be better with the combination of chemotherapy and immunotherapy than immunotherapy alone, suggests a pooled analysis by the US FDA.

People with stage II–IIIA non-small-cell lung cancer derive a significant disease-free survival benefit from adjuvant treatment with atezolizumab versus best supportive care, according to phase 3 trial results.

More information on this announcement available here

The addition of tislelizumab to first-line chemotherapy significantly improves the progression-free survival of patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer, indicate phase 3 trial results.

Read more on this decision here

Click through for more details

Nab-paclitaxel offers a similar survival benefit to docetaxel when given to previously treated patients with advanced non-small-cell lung cancer, show data from the phase 3 J-AXEL trial.

A Japanese real-world study has found higher rates of pneumonitis with first-line pembrolizumab plus chemotherapy among patients with advanced nonsquamous non-small-cell lung cancer than previously reported in clinical trials.

Second-line dacomitinib treatment is associated with a low objective response rate among patients with EGFR-mutated non-small-cell lung cancer who progress on first-line osimertinib, report US researchers.

The addition of pembrolizumab to pemetrexed–paclitaxel chemotherapy provides durable survival advantages for treatment-naïve patients with metastatic, nonsquamous non-small-cell lung cancer, the final protocol-specified analysis of KEYNOTE-189 has confirmed.

Find out more about this decision here

An extensive meta-analysis of individual participant data has not found consistent evidence to indicate that antihypertensive use is associated with an increased risk for cancer.

Chemoimmunotherapy may be a better option than immune checkpoint inhibitor monotherapy for advanced non-small-cell lung cancer patients with high PD-L1 expression and no KRAS mutations, indicate findings.

More information on these Clinical Practice Guidelines available here

Individuals with obesity tend to have worse cancer survival outcomes than those without obesity, unless they have lung cancer, renal cell carcinoma, or melanoma, show findings of a systematic review and meta-analysis.

Patients with advanced squamous non-small-cell lung cancer derive a significant overall survival benefit from second-line treatment with sintilimab versus docetaxel, suggest results from the Chinese ORIENT-3 trial.

The anti-PD-1 antibody tislelizumab may improve outcomes relative to docetaxel as a second- or third-line therapy for people with advanced non-small-cell lung cancer, regardless of histology or PD-L1 expression levels, researchers report.